Alkermes Plc · NASDAQ:ALKS

Alkermes — Q1 2025 Earnings Presentation

16 slides from Alkermes's earnings presentation, May 1, 2025

  1. Slide 1: First Quarter 2025 Financial Results & Business Update

    First Quarter 2025 Financial Results & Business Update May 1, 2025

  2. Slide 2: Forward-Looking Statements and Non-GAAP Financial Information

    Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkerm

  3. Slide 3: Q1 2025 Financial and Operational Performance

    Q1 2025 Financial and Operational Performance

  4. Slide 4: Q1 2025 Financial Results Summary

    Q1 2025 Financial Results Summary Total Revenue GAAP Net Income GAAP Earnings Per Share Diluted In millions In millions $350.4 $36.8 $0.21 $306.5 $22.5 $0.13 Q1 2024 Q1 2025 Q1 2024 Q1 2025 Q1 2024 Q1 2025 Q1 2025 results reflect expiration of royalty on U.S. net sales of INVEGA SUSTENNA® in August

  5. Slide 5: Q1 2025 Profitability

    Q1 2025 Profitability GAAP Net Income EBITDA* Adjusted EBITDA* From Continuing Operations From Continuing Operations In millions In millions In millions $38.9 $51.5 $81.8 $22.5 $45.6 $22.8 Q1 2024 Q1 2025 Q1 2024 Q1 2025 Q1 2024 Q1 2025 EBITDA represents earnings before interest, tax, depreciation a

  6. Slide 6: Q1 2025 Revenue Summary

    Q1 2025 Revenue Summary In millions Q1’25 Q1’24 Total Proprietary Net Sales $244.5 $233.5 VIVITROL® $101.0 $97.7 ARISTADA®* $73.5 $78.9 LYBALVI® $70.0 $57.0 Manufacturing & Royalty Revenue $62.0** $116.8 Total Revenue $306.5** $350.4 Amounts in the table may not sum due to rounding. *Inclusive of AR

  7. Slide 7: Alkermes: 2025 Financial Expectations

    Alkermes: 2025 Financial Expectations* Financial Expectations for (in millions) Year Ending Dec. 31, 2025 Total Revenues $1,340 – $1,430 Expected net sales of proprietary products: COGS $185 – $205 • VIVITROL® net sales of $440M – $460M R&D Expense $305 – $335 • ARISTADA® net sales of $335M – $355M

  8. Slide 8: Q1 2025 Commercial Review

    Q1 2025 Commercial Review

  9. Slide 9: LYBALVI Performance and Expectations

    LYBALVI® Performance and Expectations LYBALVI Quarterly Net Sales ($M) $90 Q1’25 LYBALVI net sales of $70.0M reflects 23% growth compared to Q1’24 $80 • Q1’25 gross-to-net deductions: ~31% $70 $60 Outlook: $50 • FY’25 net sales expected to range from $320M – $340M* $40 $30 $20 $10 $0 Q1'23 Q2'23 Q3'

  10. Slide 10: ARISTADA Performance and Expectations

    ARISTADA® Performance and Expectations ARISTADA Quarterly Net Sales* ($M) $110 Q1’25 ARISTADA net sales were $73.5M $100 Outlook: $90 • FY’25 net sales expected to range from $80 $335M – $355M†* $70 $60 $50 $40 $30 $20 $10 $0 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 *Inclusive of ARISTA

  11. Slide 11: VIVITROL Performance and Expectations

    VIVITROL® Performance and Expectations VIVITROL Quarterly Net Sales ($M) $140 Q1’25 VIVITROL net sales were $101.0M $120 Outlook: • FY’25 net sales expected to range from $100 $440M – $460M* $80 $60 $40 $20 $0 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 *These expectations were initially p

  12. Slide 12: Appendix

    Appendix

  13. Slide 13: Appendix: Amounts Included in Discontinued Operations

    Appendix: Amounts Included in Discontinued Operations Three Months Ended March (In thousands) 31, 2024 Cost of goods manufactured and sold $ -- Research and development 2,516 Selling, general and administrative --- Income tax benefit $ (396) Loss from discontinued operations, net of tax $ 2,120 13 ©

  14. Slide 14: Appendix: Financial Results GAAP to EBITDA Adjustments and Adjusted EBITDA

    Appendix: Financial Results GAAP to EBITDA Adjustments and Adjusted EBITDA Three Months Ended Three Months Ended (In millions) March 31, 2025 March 31, 2024 Net Income from Continuing Operations — GAAP $ 22.5 $ 38.9 Adjustments: Depreciation and amortization expense 7.4 8.1 Interest income (10.1) (9

  15. Slide 15: Appendix: 2025 Guidance GAAP to EBITDA and Adjusted EBITDA

    Appendix: 2025 Guidance GAAP to EBITDA and Adjusted EBITDA Year Ending (In millions) December 31, 2025 Projected Net Income — GAAP $ 190.0 Adjustments: Net interest income (30.0) Depreciation and amortization expense 30.0 Provision for income taxes 40.0 Projected EBTIDA $ 230.0 Shared-based compensa

  16. Slide 16: www.alkermes.com

    www.alkermes.com © 2025 Alkermes. All rights reserved.

Alkermes — Q1 2025 Earnings Presentation on 6ix